November 2015

Premature ejaculation Old story new insights

Ejaculatory control is culturally acquired, and premature ejaculation is the most common male sexual complaint. Integrating the new pharmacologic and traditional psychologic treatments is the best management strategy.
Published
Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine
Like

Authors

Emmanuele A. Jannini, M.D., Giacomo Ciocca, Ph.D., Erika Limoncin, Ph.D., Daniele Mollaioli, Ph.D., Stefania Di Sante, M.D., Daniele Gianfrilli, M.D., Ph.D., Francesco Lombardo, M.D., Andrea Lenzi, M.D.

Volume 104, Issue 5, Pages 1061-1073

Abstract

Conventional theories and therapies for premature ejaculation (PE) are based on assumptions not always supported by evidence. This review of the current literature on the physiology of the ejaculatory control, pathogenesis of PE, and available therapies shows that PE is still far from being fully understood. However, several interesting hypotheses have been formulated, and solid, evidence-based clinical data are currently available for dapoxetine, the unique, first-line, officially approved pharmacotherapy for PE. Further growth in the field of PE will occur only when we shift from opinion-based classifications, definitions, and hypotheses to robust, noncontroversial data grounded on evidence.

Read the full text at: http://www.fertstert.org/article/S0015-0282(15)01881-6/fulltext


Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. 

Recommended Content